|
1
|
Gladson CL, Prayson RA and Liu WM: The
pathobiology of glioma tumors. Annu Rev Pathol. 5:33–50. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kleihues P, Louis DN, Scheithauer BW,
Rorke LB, Reifenberger G, Burger PC and Cavenee WK: The WHO
classification of tumors of the nervous system. J Neuropathol Exp
Neurol. 61:215–229. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ohgaki H and Kleihues P: Population-based
studies on incidence, survival rates, and genetic alterations in
astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol.
64:479–489. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yoshimoto K, Dang J, Zhu S, Nathanson D,
Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, et al:
Development of a real-time RT-PCR assay for detecting EGFRvIII in
glioblastoma samples. Clin Cancer Res. 14:488–493. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mitchell DA, Xie W, Schmittling R, Learn
C, Friedman A, McLendon RE and Sampson JH: Sensitive detection of
human cytomegalovirus in tumors and peripheral blood of patients
diagnosed with glioblastoma. Neuro Oncol. 10:10–18. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Masui K, Cloughesy TF and Mischel PS:
Review: Molecular pathology in adult high-grade gliomas: From
molecular diagnostics to target therapies. Neuropathol Appl
Neurobiol. 38:271–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dunn GP, Rinne ML, Wykosky J, Genovese G,
Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, et
al: Emerging insights into the molecular and cellular basis of
glioblastoma. Genes Dev. 26:756–784. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park JK, Hodges T, Arko L, Shen M, Dello
Iacono D, McNabb A, Olsen Bailey N, Kreisl TN, Iwamoto FM, Sul J,
et al: Scale to predict survival after surgery for recurrent
glioblastoma multiforme. J Clin Oncol. 28:3838–3843. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sampson JH, Archer GE, Mitchell DA,
Heimberger AB and Bigner DD: Tumor-specific immunotherapy targeting
the EGFRvIII mutation in patients with malignant glioma. Semin
Immunol. 20:267–275. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sampson JH, Archer GE, Mitchell DA,
Heimberger AB, Herndon JE II, Lally-Goss D, McGehee-Norman S,
Paolino A, Reardon DA, Friedman AH, et al: An epidermal growth
factor receptor variant III-targeted vaccine is safe and
immunogenic in patients with glioblastoma multiforme. Mol Cancer
Ther. 8:2773–2779. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dix AR, Brooks WH, Roszman TL and Morford
LA: Immune defects observed in patients with primary malignant
brain tumors. J Neuroimmunol. 100:216–232. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wilson EH, Weninger W and Hunter CA:
Trafficking of immune cells in the central nervous system. J Clin
Invest. 120:1368–1379. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kuppner MC, Hamou MF, Sawamura Y, Bodmer S
and de Tribolet N: Inhibition of lymphocyte function by
glioblastoma-derived transforming growth factor beta 2. J
Neurosurg. 71:211–217. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bodmer S, Strommer K, Frei K, Siepl C, de
Tribolet N, Heid I and Fontana A: Immunosuppression and
transforming growth factor-beta in glioblastoma. Preferential
production of transforming growth factor-beta 2. J Immunol.
143:3222–3229. 1989.PubMed/NCBI
|
|
16
|
Parsa AT, Waldron JS, Panner A, Crane CA,
Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et
al: Loss of tumor suppressor PTEN function increases B7-H1
expression and immunoresistance in glioma. Nat Med. 13:84–88. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fecci PE, Mitchell DA, Whitesides JF, Xie
W, Friedman AH, Archer GE, Herndon JE II, Bigner DD, Dranoff G and
Sampson JH: Increased regulatory T-cell fraction amidst a
diminished CD4 compartment explains cellular immune defects in
patients with malignant glioma. Cancer Res. 66:3294–3302. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hussain SF, Yang D, Suki D, Aldape K,
Grimm E and Heimberger AB: The role of human glioma-infiltrating
microglia/macrophages in mediating antitumor immune responses.
Neuro Oncol. 8:261–279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou M, Wiemels JL, Bracci PM, Wrensch MR,
McCoy LS, Rice T, Sison JD, Patoka JS and Wiencke JK: Circulating
levels of the innate and humoral immune regulators CD14 and CD23
are associated with adult glioma. Cancer Res. 70:7534–7542. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schlehofer B, Blettner M, PrestonMartin S,
Niehoff D, Wahrendorf J, Arslan A, Ahlbom A, Choi WN, Giles GG,
Howe GR, et al: Role of medical history in brain tumour
development. Results from the international adult brain tumour
study. Int J Cancer. 82:155–160. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lachance DH, Yang P, Johnson DR, Decker
PA, Kollmeyer TM, McCoy LS, Rice T, Xiao Y, AliOsman F, Wang F, et
al: Associations of high-grade glioma with glioma risk alleles and
histories of allergy and smoking. Am J Epidemiol. 174:574–581.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lohr J, Ratliff T, Huppertz A, Ge Y,
Dictus C, Ahmadi R, Grau S, Hiraoka N, Eckstein V, Ecker RC, et al:
Effector T-cell infiltration positively impacts survival of
glioblastoma patients and is impaired by tumor-derived TGF-β. Clin
Cancer Res. 17:4296–4308. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kmiecik J, Poli A, Brons NH, Waha A, Eide
GE, Enger PØ, Zimmer J and Chekenya M: Elevated CD3+ and
CD8+ tumor-infiltrating immune cells correlate with
prolonged survival in glioblastoma patients despite integrated
immunosuppressive mechanisms in the tumor microenvironment and at
the systemic level. J Neuroimmunol. 264:71–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vauléon E, Tony A, Hamlat A, Etcheverry A,
Chiforeanu DC, Menei P, Mosser J, Quillien V and Aubry M: Immune
genes are associated with human glioblastoma pathology and patient
survival. BMC Med Genomics. 5:412012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pino PA and Cardona AE: Isolation of brain
and spinal cord mononuclear cells using percoll gradients. J Vis
Exp. pii:23482011.
|
|
27
|
Randolph GJ, Jakubzick C and Qu C: Antigen
presentation by monocytes and monocyte-derived cells. Curr Opin
Immunol. 20:52–60. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Malek TR: The biology of interleukin-2.
Annu Rev Immunol. 26:453–479. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huettner C, Paulus W and Roggendorf W:
Messenger RNA expression of the immunosuppressive cytokine IL-10 in
human gliomas. Am J Pathol. 146:317–322. 1995.PubMed/NCBI
|
|
30
|
Samaras V, Piperi C, Korkolopoulou P,
Zisakis A, Levidou G, Themistocleous MS, Boviatsis EI, Sakas DE,
Lea RW, Kalofoutis A and Patsouris E: Application of the ELISPOT
method for comparative analysis of interleukin (IL)-6 and IL-10
secretion in peripheral blood of patients with astroglial tumors.
Mol Cell Biochem. 304:343–351. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rossol M, Heine H, Meusch U, Quandt D,
Klein C, Sweet MJ and Hauschildt S: LPS-induced cytokine production
in human monocytes and macrophages. Crit Rev Immunol. 31:379–446.
2011. View Article : Google Scholar : PubMed/NCBI
|
